T his month marks the 50th anniversary of the discovery of Epstein-Barr virus (EBV) as the fi rst human tumor virus. In March 1964, a team led by Anthony Epstein identifi ed herpesvirus-like particles in cultured tumor cells derived from African Burkitt's lymphoma tissue ( 1) . At that time, the idea that a virus caused human cancer was met with some skepticism because the theory that cancer was infectious had been dismissed in the previous century. Stalwart investigators continued to track EBV until the viral culprit was declared a class I carcinogen by the International Agency for Research on Cancer and the World Health Organization in the late 1990s. Despite the consensus that EBV is a bona fi de tumor virus, the mechanisms of cancer causation by EBV remain an area of active investigation and controversy 50 years since its initial discovery.
One of the most confounding findings relating to the association of EBV with rare cancers is that EBV prevalence in the normal population is extraordinarily high, reaching over 90% of the adult population worldwide. Because EBV is a member of the herpesvirus family, it is very adept at establishing a long-term latent infection. Exposure to EBV can be detected by serology, and latent forms of EBV can be readily detected by molecular methods in a small percentage of B lymphocytes from healthy individuals. Furthermore, EBV was identified as a major causative agent of infectious mononucleosis, which seemed incongruent with its role in cancer causality. How could a relatively common virus be the cause of an endemic childhood cancer in Africa?
Viral causes of animal cancers had been known since 1911, when Peyton Rous discovered that retroviruses cause cancers in chickens. But it was not until the discovery in 1968 that viruses related to EBV were responsible for T cell lymphomas in nonhuman primates that the case for EBV-dependent tumorigenesis became more compelling. EBV was soon found to be highly effi cient at transforming quiescent human B lymphocytes into contin-
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104-4265, USA. E-mail: lieberman@wistar.org opment of the yolk sac. This phenotype was reminiscent of mice that lack Fadd or caspase 8. While mice lacking Fadd or caspase 8 succumbed to extensive necrosis during embryogenesis, the lethality in RIPK3-D161N mice was caused by extensive caspase-dependent apoptosis. Mice expressing RIPK3-D161N and also lacking caspase 8 were normal, but developed a lymphoproliferative disease akin to that caused by inactivating mutations in Fas, a member of the TNF receptor family that stimulates apoptosis. Newton et al. show that induced expression of RIPK3-D161N in adult mice triggered the formation of a complex containing Fadd, caspase 8, RIPK1, and RIPK3 that caused massive apoptosis in multiple tissues and lethality. Although RIPK1 is present in this death-inducing complex, blocking its kinase activity did not prevent apoptosis. Moreover, embryonic lethality of RIPK3-D161N mice was rescued by RIPK1 defi ciency. Thus, although there is an overlapping set of proteins (Fadd, caspase 8, RIPK1, and RIPK3) that are involved in necroptosis and RIPK3-D161N-induced apoptosis, the molecular mechanisms that drive these two cell death responses are distinct.
How can we reconcile the lethal phenotype of RIPK3-D161N mice when animals lacking RIPK3 were born alive with no overt abnormalities? One explanation is that RIPK3 phosphorylates and inactivates a substrate that prevents assembly of the Fadd-caspase 8-RIPK1-RIPK3 death-inducing complex (see the fi gure). In this regard, it is noteworthy that the activities of Fadd, RIPK1, and RIPK3 are controlled by phosphorylation ( 3, 4) . Perhaps RIPK3 directly phosphorylates one or more of these proteins to control the assembly of this RIPK3-associated apoptosis-inducing complex.
Although inhibition of RIPK3 kinase activity is a plausible cause of apoptosis in RIPK3-D161N cells and mice, other mechanisms are also possible. For example, mice that express a single allele of D161N were viable. Because gene dosage is important, the phenotypes cannot be entirely attributed to lack of kinase activity. Previous studies show that a form of RIPK3 in which the kinase domain has been deleted causes spontaneous formation of RIP homotypic interaction motif ( 5) (RHIM)-dependent amyloid fi brils ( 6) . This indicates that the kinase domain may functionally "mask" the RHIM to prevent inadvertent activation. In this scenario, the D161N mutation could alter the conformation of RIPK3 such that the RHIM is exposed for binding to RIPK1. This model predicts that the kinase and RHIM domains collaborate to control scaffolding of the necroptotic and apoptotic machineries. This type of scaffolding function for kinase domains has been observed with oncogenic kinases such as B-Raf ( 7). Interestingly, a much lower amount of RIPK3-D161N was expressed compared to wild-type RIPK3, which may be attributed to a conformational change that leads to protein instability. The therapeutic effi cacy of RIPK3 kinase inhibitors ( 8) will depend on whether they similarly promote assembly of this apoptosis scaffold. In contrast to RIPK3 ( 9) , mice expressing kinase inactive RIPK1 were viable ( 1) . As such, pharmacologic inhibition of RIPK1 may prove to be a more viable option in the clinic.
Although compelling evidence indicates that RIPK3 does not participate in death receptor-induced apoptosis, RIPK3 was originally identifi ed as an inducer of apoptosis (10) (11) (12) . Newton et al. show that regardless of the mechanism, RIPK3 can indeed function as an apoptosis regulator. In that sense, RIPK3 biology has come full circle. The challenge is to determine how RIPK3-dependent apoptosis is induced and whether it has any unique functions in physiology.
PERSPECTIVES uously proliferating lymphoblastoid cell lines ( 2) , and EBV is now a common laboratory tool used to immortalize B lymphocytes for human genetic studies. The search for additional cancers that contain EBV revealed that latent forms of the virus were present in most nasopharyngeal carcinomas endemic to Southeast Asia. Although EBV is found in ~100% of this cancer type, it was only found in a third of these carcinomas outside of endemic regions, similar to what was found for Burkitt's lymphoma (cancer of B lymphocytes). These imperfect correlations fueled concerns that EBV was not a driver of oncogenesis but merely an opportunistic passenger in cancer, and that high correlations could be attributed to increased viral load in endemic regions.
The discovery of EBV as a causative agent of X-linked lymphoproliferative disease, a rare genetic disorder of immunologic dysfunction, illuminated the importance of host immunologic status in the control of viral-associated malignancies. Moreover, during the era of the HIV-AIDS epidemic and before successful antiviral therapies, the prevalence of B cell lymphomas and Kaposi's sarcomas revealed the opportunistic nature of these malignancies. The massive depletion of CD4 T cells and immune dysfunction in HIV-AIDS is sufficient to unleash the potential of latent EBV to drive immunoblastic large B cell lymphomas. The insight that immunosuppression could drive malignancy fueled the search for a causative agent for Kaposi's sarcoma, and led Yuan Chang and Patrick Moore to identify a second human gammaherpesvirus linked to human cancer ( 3) . Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV8), has a near perfect correlation with all forms of Kaposi's sarcoma, and also with some B cell malignancies, including pleural effusion lymphomas. The identifi cation of KSHV as a second human tumor virus from the gammaherpesvirus fi eld solidifi ed the argument that these viruses have a causative role in human cancer.
Infectious agents in cancer were found to be more common than originally thought. In the early 1990s, Helicobacter pylori was shown to cause peptic ulcer diseases, a fi nding that was recognized with the 2005 Nobel Prize to Robin Warren and Barry Marshall. This fi nding opened the door to linking the bacterium with gastric carcinoma. Interestingly, EBV has been consistently found in ~10% of all stomach cancers and is now recognized as a distinct subtype of the cancer. The most compelling case for virus-associated cancer has been made for human papillomaviruses (HPVs) and cervical carcinoma. All forms of cervical carcinoma contain a subtype of HPV that corresponds to a high-risk viral genome. The distinction between low-and high-risk viral genomes provided one explanation for how a common virus could be associated with relatively rare forms of cancer. The high-risk strains of HPV are more likely to develop cancer. The discovery that HPV was the etiological agent of cervical and oral squamous cell carcinomas resulted in a Nobel Prize shared by Harald zur Hausen (2008). To date, the number of viruses or infectious agents associated directly or indirectly with human cancer etiology has grown to include the human hepatocellular carcinoma viruses (hepatitis C and B viruses), T cell leukemia virus (human T-lymphotropic virus I and II), and the Merkel cell carcinoma virus. In all, it is estimated that infectious agents are responsible for one-fi fth of all cancers ( 4).
In addition to being the first human cancer virus to be discovered, EBV was also the first large herpesvirus genome to be completely sequenced (1995), a project that helped launch the genomic era ( 5) . Long thought to have a highly conserved genome with only two major subtypes, recent studies suggest that additional polymorphisms may explain the variation in cancer risk, similar to that observed in HPVs ( 6) . The EBV genome encodes close to 100 open reading frames, several of which are expressed consistently in human cancers [EBV nuclear antigen 1 (EBNA1); latent membrane protein 1 (LMP1)], and some of which have growth-transforming activity and are essential for EBV immortalization of B cells in vitro and tumorigenesis in animal models (LMP1, EBNA2, EBNA3C). Its mechanisms of viral subterfuge include encoding viral pirates of the B cell receptor, CD40-like co-receptors, and the Notch family of transcription regulators ( 7) . The EBV genome also encodes over 20 microRNAs and other noncoding RNAs that are expressed at high amounts in human cancers and have tumorigenic properties, including the potential to be transmitted via exosomes to noninfected neighboring cells ( 8) . EBV can adopt variant gene expression patterns that enhance its adaptability and help it to evade host immune recognition. EBV latent infection can also epigenetically suppress host tumor suppressor genes, providing a potential "hit and run" mechanism for viral oncogenesis ( 9) .
Although there is a vaccine for HPV ( 10) , none yet exists for EBV. At least one effort to develop a vaccine targeting the EBV glycoprotein gp350 was effective in reducing the incidence of infectious mononucleosis ( 11), but did not prevent the occurrence of latent infection, raising concern that the vaccine would not prevent most EBV-associated cancer. B cell lymphomas arising from EBV have been successfully treated by adoptive immunotherapy ( 12) , but this approach has proven labor intensive and technologically challenging. Thus far, there are no selective treatments for EBV-associated disease, although efforts are under way to develop both biological and pharmacological inhibitors of viral proteins and oncogenes. And as more diseases with potential links to EBV infection are revealed, such as multiple sclerosis and lupus erythematosis ( 13) , the need
CREDIT: V. ALTOUNIAN/SCIENCE
Half-century mark. Epstein-Barr virus was discovered 50 years ago by Anthony Epstein. The details of its association with cancer remain enigmatic, and an effective therapy has yet to be developed.
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Flow of Control in Networks
PHYSICS
A simple framework allows the classifi cation of complex networks based on the fl ow of control.
M any complex systems can be viewed as networks, in which nodes represent system elements and edges correspond to interactions between those elements. In such networks, a subset of nodes-the driver nodes-can yield control of the entire network when they are driven by external signals ( 1-3) . However, to control a system, one must know not only what parts need to be controlled but also why these particular parts need to be controlled. On page 1373 of this issue, Ruths and Ruths ( 4) put forward an elegant framework that elucidates the origin of control in networks. The framework divides nodes into three categories based on how they affect the fl ow of control in networks. This approach gives rise to control profi les that the authors use to classify a host of empirical and synthetic networks. The results suggest that networks from different domains but in the same category may be more similar to one another than previously thought.
To understand the idea of network control, consider a dynamical process that unfolds on a network, such as an airport transportation network, where the state of a node encodes the number of passengers at that node. If a directed edge leads from node A to node B, then the state of node A infl uences the state of node B. The system is controllable if it can be driven from an arbitrary initial state to a specifi ed fi nal state in a fi nite time. In the absence of loops and cycles, each node can control at most one of its neighbors ( 5) . Together, these node-to-neighbor couplings give rise to disjoint directed paths of control in the network; each path, or stem, needs its own independent control. If we can identify the stems, we can control the network.
The standard way to fi nd the set of controllable nodes is to use the maximum matching algorithm ( 6) , where "maximum matching" refers to the maximum set of edges that do not share start or end nodes ( 1) . A node is matched if an edge in the maximum matching points to it; otherwise, it is unmatched and needs its own independent control. If all stems were simple directed paths (see the fi gure, panel A), the number of independently controlled nodes would equal the number of source nodes, which are nodes with no incoming edges. Control-inducing structures in networks. In a simple directed path or stem (A), only the source node needs to be controlled. If a stem branches, either internal dilations (B) or external dilations (C) are introduced, both of which increase the number of nodes that need independent control. This is because each node can control at most one of its neighbors and at a dilation a node has more than one neighbor. In panel C, the number of nodes that need independent control coincides with the number of sink nodes (nodes with no outgoing edges); this is not the case in panel B. Ruths and Ruths show that each control-inducing structure can be classifi ed as a source node, an internal dilation, or an external dilation, and that the control profi le of a network is the relative frequency with which each type occurs in the network.
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for personalized therapies for treating EBV will continue to grow. To date, EBV is estimated to be responsible for ~200,000 cancers worldwide ( 4) . The U.S. National Institutes of Health (NIH) recently called for a new initiative to reduce global cancer incidence, with EBV among the top candidates for future advances ( 14) . Further clinical testing of the gp350 vaccine, as well as development of second-generation vaccines and diagnostics to measure vaccine effi cacy and cancer risk factors, have been recommended by an NIH-sponsored panel ( 14, 15) . Among the new generation of vaccines will be those that treat latently infected individuals with existing EBV-driven cancers as well as those that are at high risk for developing EBV-associated disease (e.g., solid organ transplant recipients). Any vaccine that stimulates a strong and selective T cell response to EBV-positive tumor cells is likely to provide protection and therapeutic benefi t. It is to be hoped that the successes of HPV and hepatitis B virus vaccination programs will encourage new and ongoing efforts to fi nd a suitable immunological or pharmacological treatment for EBV and associated disease. An effi cacious antiviral would also provide the fi nal confirmation that EBV is indeed a tumorcausing virus.
